# Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

> **NCT02214407** · PHASE3 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 170 (actual)

## Conditions studied

- MDS

## Interventions

- **DRUG:** Decitabine
- **DRUG:** HYDROXYUREA

## Key facts

- **NCT ID:** NCT02214407
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-14
- **Primary completion:** 2021-07-05
- **Final completion:** 2021-08-16
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2021-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214407, "Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02214407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*